Teduglutide
Gattex · Revestive · ALX-0600
An FDA-approved GLP-2 analog that stimulates intestinal epithelial growth and reduces parenteral nutrition dependence in short bowel syndrome, with research interest in gut barrier repair and intestinal regeneration.
Half-Life
~1.8-2 hours (SC)
MW
3752.2 Da
Amino Acids
33 AA
Evidence
High Evidence
Regulatory Status
FDA-approved (2012, Gattex) and EMA-approved (Revestive) for SBS-associated intestinal failure. Prescription-only. Subcutaneous daily injection.
In Plain English
A stabilized version of the gut's own growth signal (GLP-2) that tells the intestinal lining to grow thicker, with more surface area and stronger barriers. FDA-approved for people with short bowel syndrome who need intravenous feeding — teduglutide helps their remaining gut compensate by growing larger. Researchers are interested in its gut repair properties for leaky gut, IBD, and chemotherapy damage.
Overview
Teduglutide is a 33-amino acid GLP-2 analog with an Ala2→Gly2 substitution that prevents DPP-IV inactivation, extending its half-life from ~7 minutes (native GLP-2) to ~2 hours. FDA-approved in 2012 for short bowel syndrome (SBS) with intestinal failure in adults and children. GLP-2 is the sister incretin to GLP-1 — both cleaved from proglucagon by L-cell PC1/PC3 — but GLP-2 primarily acts on the intestinal epithelium rather than the pancreas. In SBS patients, teduglutide increases villus height, crypt depth, intestinal mucosal surface area, and intestinal blood flow, enabling progressive weaning from total parenteral nutrition (TPN). In the research community, teduglutide and native GLP-2 are studied for gut barrier integrity, leaky gut, IBD, chemotherapy-induced mucositis, and GI recovery protocols.
Common Formats
- Subcutaneous injection (0.05 mg/kg/day clinical; research doses vary)
Storage Notes
Lyophilized: refrigerate 2-8°C. Reconstituted: use within 3 hours at room temperature, or 24 hours refrigerated. Do not freeze reconstituted solution.
Looking for multi-compound protocols?
Browse educational protocol discussions that include Teduglutide.
Related Compounds
GLP-2
Intestinotrophic hormone that promotes gut epithelial growth, repair, and nutrient absorption — clinically used for short bowel syndrome.
BPC-157
A 15 amino acid peptide derived from human gastric juice, widely researched for its tissue-healing and cytoprotective properties.
KPV
C-terminal tripeptide fragment of alpha-MSH with potent anti-inflammatory and gut-healing properties.
Semaglutide
A GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity, demonstrating unprecedented weight loss results in clinical trials.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.